Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR1 | P21462 | 2/20 | 0.44 |
| ▸ | FPR2 | P25090 | 2/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4263614 | 1.00 | FPR1 (0.44) | FPR1FPR2PDGFRBFGFR1KDR | |
| SCHEMBL31084534 | 1.00 | FPR1 (0.44) | FPR1FPR2PDGFRBFGFR1KDR | |
| SCHEMBL20374556 | 0.91 | NPY5R (0.41) | FPR1FPR2NTRK1NPY5R | |
| SCHEMBL29276828 | 0.87 | KDR (0.43) | PDGFRBFGFR1KDRMAP4K4MCHR1 | |
| SCHEMBL29276789 | 0.87 | KDR (0.43) | PDGFRBFGFR1KDRMAP4K4MCHR1 | |
| SCHEMBL29276792 | 0.87 | KDR (0.43) | PDGFRBFGFR1KDRMAP4K4MCHR1 | |
| SCHEMBL1750696 | 0.84 | NOTUM (0.44) | FPR1FPR2MAP4K4MCHR1NOTUM | |
| SCHEMBL1749372 | 0.84 | NOTUM (0.44) | FPR1FPR2MAP4K4MCHR1NOTUM | |
| SCHEMBL4291539 | 0.84 | MCHR1 (0.49) | FPR1FPR2MAP4K4MCHR1NOTUM | |
| SCHEMBL24681112 | 0.84 | FPR1 (0.43) | FPR1FPR2MCHR1NTRK1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828991-B2 | Azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments | SANOFI (FR) | 2014-09-09 | — | — | US | disclosed |
| US-20090082339-A1 | NOVEL AZACYCLYL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-03-26 | — | — | US | disclosed |
| CN-101370501-A | Novel azacycly-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments | SANOFI AVENTIS (FR) | 2009-02-18 | — | — | CN | disclosed |
| EP-1986646-A1 | NOVEL AZACYCLY-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | Sanofi-Aventis (FR) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093363-A1 | NOVEL AZACYCLY-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (DE) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082339-A1 | NOVEL AZACYCLYL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | MCHR1, MPI, TPMT | FPR1 1347/4885FPR2 1236/4885PDGFRB 3375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.